Visual Function Tests in Age-related Macular Degeneration

NCT ID: NCT03275753

Last Updated: 2024-04-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-21

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Age-related macular degeneration (AMD) is one of the leading causes of visual impairment among elderly populations in developed countries. Majority of AMD patients (80%) suffer from the dry or non-exudative form of the disease. Currently there are no approved treatments for dry AMD. Clinical development of therapeutic agents for dry AMD is limited by slow progressing nature of the disease as well as the lack of sensitive endpoints to assess therapeutic efficacy. Visual acuity, the commonly used functional endpoint, remains minimally affected during early stages of dry AMD. Thus novel visual function endpoints, that can identify functional deficits during early stages of dry AMD prior to development of geographic atrophy, are needed. In the current study a battery of visual function tests will be evaluated in subjects with different stages of dry AMD and normal controls, to assess their sensitivity and feasibility as potential functional endpoints for dry AMD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age Related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Population

VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases

Visual Function Tests

Intervention Type OTHER

All subjects will undergo a battery of visual function tests

Early Dry AMD Population

VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD

Visual Function Tests

Intervention Type OTHER

All subjects will undergo a battery of visual function tests

Intermediate Dry AMD Population

VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD

Visual Function Tests

Intervention Type OTHER

All subjects will undergo a battery of visual function tests

Advanced Dry AMD Population

Clinical diagnosis of advanced dry AMD in the study eye

Visual Function Tests

Intervention Type OTHER

All subjects will undergo a battery of visual function tests

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual Function Tests

All subjects will undergo a battery of visual function tests

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All Subjects Must:

1. Be 60 years of age or older;
2. Provide written informed consent;
3. Be willing and able to follow all instructions and attend the study visits;
4. Must be able to perform all study procedures;

Normal Subjects:
5. Have BCVA of 20/25 or better in the study eye;
6. Have no history or clinical evidence of AMD, retinal diseases or any other ocular pathologies in either eye;

AMD Subjects:
7. Have BCVA of 20/40 or better in the study eye;
8. Have a clinical diagnosis of non-exudative AMD in the study eye;

Exclusion Criteria

All subjects must not have any of the below criteria

<!-- -->

1. Have a diagnosis of wet AMD in the study eye;
2. Have any other hereditary or acquired retinal diseases in either eye ;
3. Have glaucoma or other optic nerve diseases in either eye;
4. Have corneal or other anterior segment diseases in either eye;
5. Have significant cataract in the study eye;
6. Have a history of ocular trauma or ocular surgery (other than cataract removal) in the study eye;
7. Have a history of uncontrolled systemic disease (e.g. poorly controlled hypertension or poorly controlled diabetes);
8. Have a history of seizures;
9. On psychotropic medications;
10. Any other symptoms or conditions that could, in the opinion of the investigator, interfere with study procedures.
Minimum Eligible Age

60 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ORA, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jason Chin, OD

Role: PRINCIPAL_INVESTIGATOR

ORA, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Andover Eye Associates

Andover, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-270-0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.